Use Acura Pharmaceuticals Inc. media headlines with your portfolios to protect against small markets fluctuations as well as to determine Stock diversification method that is right for you.
Acura Pharmaceuticals to Host First Quarter 2012 Financial Results Conference ...
MarketWatch (press release) - 6 hours ago
PALATINE, IL, Apr 24, 2012 (MARKETWIRE via COMTEX) -- Acura Pharmaceuticals, Inc. (UTD:ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the company plans to report financial results for the first quarter ...
MMD Newswire (press release) - Mar 23, 2012
PALATINE, IL (MMD Newswire) March 23, 2012 -- William Skelly sold 5000 shares of Acura Pharmaceuticals, Inc stock, or $20600 worth, as noted in an SEC Filing today.
Acura Pharmaceuticals to Present at the Needham Healthcare Conference on April ...
SYS-CON Media (press release) - Mar 21, 2012
By Marketwire . PALATINE, IL -- (Marketwire) -- 03/21/12 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today that the company will present at the 11th Annual Needham ...
Here are today's Strong Volume Gainers for Tuesday 03/20/2012. In focus today is the Biotechnology sector. Those not buying the dip may commit ritual Seppuku tomorrow.
Acura Pharmaceuticals (ACUR) is a specialty pharmaceutical company that engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies.
Seeking Alpha - Mar 11, 2012
When investing in young, small biotech companies, investors take on the risk of whether a company can become profitable, whether drugs can meet FDA approval, whether adequate funding is available to develop and market drugs, and whether the small ...
RTT News - Mar 5, 2012
(RTTNews) - Acura Pharmaceuticals, Inc. (ACUR: News ) reported a net loss applicable to common stockholders for the fourth-quarter of $1.62 million or $0.03 per share, narrower than $2.9 million or $0.06 per share in the year-ago quarter.
Stock in News at Healthcare Sectors- ACUR, PFE, AMRN - eStocksDaily
By Sam Mattera In recent years, traders and investors have increasingly turned to social media to discuss their investments. Now, interested parties can get a scientific look at what is being discussed on a weekly, monthly, and even hourly basis.
Acura Pharmaceuticals to Report Fourth Quarter and Fiscal Year 2011 Financial ...
MarketWatch (press release) - 23 hours ago
PALATINE, IL, Feb 23, 2012 (MARKETWIRE via COMTEX) -- Acura Pharmaceuticals, Inc. (UTD:ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the company plans to report financial results for the fourth ...
Kahn Swick & Foti, LLC Announces Scheduling Changes Regarding Acura ...
MarketWatch (press release) - 2 hours ago
NEW ORLEANS, Feb 13, 2012 (GlobeNewswire via COMTEX) -- Kahn Swick & Foti, LLC announces that on February 13, 2012, Judge Virginia M. Kendall of the United States District Court Northern District of Illinois Eastern Division made changes regarding the ...
Seeking Alpha - Feb 9, 2012
If you're looking for a stock that could double over the next 12 months, your best bet is biotechnology. Using the Google (GOOG) screener, I found that 51 stocks with a market capitalization greater than $50 million had returned one-year gains of at ...
Bloomberg - Jan 24, 2012
Acura Pharmaceuticals Inc. (ACUR), a maker of technology to deter drug abuse, rose after its short-acting painkiller marketed by Pfizer Inc. (PFE) became commercially available.
Acura Pharmaceuticals Provides Update on Opioid Product Licensed to Pfizer - MarketWatch (press release)
Pfizer Informs Acura That OXECTA Tablets CII Is Now Commercially Available - NASDAQ
Based on latest financial disclosure Acura Pharmaceuticals Inc. has Total Debt of 0.0. This is 100.0% lower than that of Healthcare sector, and 100.0% lower than that of Drug Delivery industry, The Total Debt for all stocks is 100.0% higher than the company.
In most industries, total debt may also include current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meaningful to compare total debt amounts between companies that operate within the same sector.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
